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Objective
To complete validation of the Juvenile Arthritis Disease
Activity Score.
Materials and methods
The JADAS is composed of the following measures: 1)
physician's global assessment (0–10); 2) parent's global
assessment (0–10); 3) active joint count (assessed in 71,
27 or 10 joints); 4) ESR (normalized to 0–10). It yields a
score ranging from 0 to 40, 57 or 101, depending on
whether the whole 71-joint count (JADAS-71) or the 27-
joint (JADAS-27) or 10-joint (JADAS-10) reduced counts
are used. The 3 versions of the JADAS were tested on juve-
nile idiopathic arthritis patients included in 2 trials on
methotrexate (n = 595) and meloxicam (n = 225). Con-
struct validity was assessed by calculating Spearman's cor-
relation between baseline-endpoint changes in JADAS, C-
HAQ and 2 adult scores (DAS28, CDAI). Discriminative
validity was assessed by examining the ability of JADAS to
discriminate between different levels of ACR Pediatric
response in the 2 trials.
Results
Table 1 shows Spearman's correlations on changes in the
2 clinical trials.
Conclusion
Overall, the JADAS versions including the reduced joint
counts (either 27 or 10) revealed better or, at least, similar
validity as compared with the version including the 71
(i.e. complete) joint count. Use of JADAS versions with
reduced joint counts is advised due to their greater feasi-
bility.
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Table 1: Spearman's correlations on changes in the 2 clinical trials
Methotrexate trial Meloxicam trial
JADAS-71 JADAS-27 JADAS-10 JADAS-71 JADAS-27 JADAS-10
CHAQ 0.46 0.50 0.51 0.44 0.43 0.45
DAS28 0.78 0.80 0.79 0.74 0.74 0.70
CDAI 0.88 0.86 0.72 0.87 0.86 0.75
The JADAS-10 revealed the best discriminative validity, followed by the JADAS-27 and the JADAS-71.